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Abstract
Purpose The prevalence of type 2 diabetes mellitus (T2DM) is increasing worldwide. For this reason, it is essential to iden-
tify biomarkers for the early detection of T2DM risk and/or for a better prognosis of T2DM. We aimed to identify a plasma 
fatty acid (FA) profile associated with T2DM development.
Methods We included 462 coronary heart disease patients from the CORDIOPREV study without T2DM at baseline. Of 
these, 107 patients developed T2DM according to the American Diabetes Association (ADA) diagnosis criteria after a median 
follow-up of 60 months. We performed a random classification of patients in a training set, used to build a FA Score, and a 
Validation set, in which we tested the FA Score.
Results FA selection with the highest prediction power was performed by random survival forest in the Training set, which 
yielded 4 out of the 24 FA: myristic, petroselinic, α-linolenic and arachidonic acids. We built a FA Score with the selected 
FA and observed that patients with a higher score presented a greater risk of T2DM development, with an HR of 3.15 (95% 
CI 2.04–3.37) in the Training set, and an HR of 2.14 (95% CI 1.50–2.84) in the Validation set, per standard deviation (SD) 
increase. Moreover, patients with a higher FA Score presented lower insulin sensitivity and higher hepatic insulin resistance 
(p < 0.05).
Conclusion Our results suggest that a detrimental FA plasma profile precedes the development of T2DM in patients with 
coronary heart disease, and that this FA profile can, therefore, be used as a predictive biomarker.
Clinical Trials.gov.Identifier NCT00924937.
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Introduction
The prevalence of type 2 diabetes mellitus (T2DM) has 
increased worldwide over the last few years and is expected 
to grow substantially over the next few decades. Character-
ized by elevated blood glucose levels, the etiology of T2DM 
is complex, and insulin resistance (IR) and impaired beta-
cell function are critical determinants of this disease [1]. 
Lifestyle factors, including physical inactivity and unhealthy 
diets, are important factors contributing to T2DM devel-
opment [2]. Patients with T2DM are at higher risk of car-
diovascular disease (CVD), a class of diseases that involve 
the heart or blood vessels, and most deaths of diabetic 
patients are due to this pathology [3]. In this context, the 
simultaneous presence of both CVD and T2DM consider-
ably increases the risk of macrovascular complications and 
mortality [4]. It is, therefore, especially important to devise 
strategies to prevent the development of T2DM in patients 
with CVD.
Lifestyle modifications, such as physical exercise and a 
healthy diet, may delay the appearance of T2DM or even 
prevent the development of this disease [5]. In this context, 
a low-fat (LF) diet or a Mediterranean (MED) diet have been 
put forward as reasonable ways to delay T2DM development 
[6, 7]: the MED diet, rich in olive oil, seems to provide 
cardiovascular benefits and increase insulin sensitivity [7] 
and the LF diet contains < 30% energy from total fat and is 
recommended by the American Diabetes Association (ADA) 
[8].
The importance of nutrition in the management and pre-
vention of T2DM through its effect on weight and metabolic 
control is clear [9]. However, nutritional strategies are not 
fully effective and/or their effectiveness is dependent on the 
individual. In short, despite dietary recommendations, there 
is no globally supported diet to prevent diabetes, and popu-
lation-specific and individual factors may determine success 
in preventing T2DM using different nutritional strategies [5]. 
Therefore, the identification of biomarkers for early detec-
tion of T2DM risk and/or better prognosis of T2DM and 
to assess the efficacy of targeted interventions is essential.
In the last few years, several studies have shown that 
plasma lipid species are a determinant factor for T2DM 
development, suggesting that changes in this profile may 
trigger the development of this disease. For example, a 
plasma lipidomic profile has been described for T2DM pre-
diction in a high cardiovascular risk population [10], and has 
also been described for evaluating the cardiovascular risk 
[11]. Moreover, the specific fatty acids (FA) composition in 
plasma phospholipids has also been shown to be useful for 
assessing T2DM risk [12]. Here, several works have studied 
the association between FA and the probability of diabetes 
development. However, most of these studies analyzed indi-
vidual FA or FA groups, such as saturated FA [13, 14] or 
polyunsaturated omega 3 or 6 [15–17], rather than analyzing 
the full FA profile. In fact, FA are not merely a source of 
energy, but play vital roles in metabolic homeostasis, serving 
as precursors of signaling molecules, and are basic compo-
nents involved in the architecture and function of cellular 
membranes and functional lipids, binding to various recep-
tors and transcription factors [18, 19].
Based on this previous evidence, we hypothesized that a 
specific plasma FA profile rather individual fatty acids may 
precede T2DM development in coronary heart patients, and, 
therefore, could be used as a biomarker to assess T2DM risk. 
We aimed to evaluate the plasma FA profile as an associated 
biomarker for T2DM development in the non-T2DM coro-
nary heart disease patients from the CORDIOPREV study.
Material and methods
Study subjects
The current work was conducted within the framework of 
the Coronary Diet Intervention with Olive Oil and Cardio-
vascular Prevention study (CORDIOPREV; Clinical Trials.
gov.Identifier: NCT00924937), an ongoing prospective, 
randomized, open, controlled trial of 1002 patients with 
coronary heart disease (CHD), which develops when the 
coronary arteries become too narrow by atherosclerotic pro-
cesses, who were receiving conventional treatment and had 
their last coronary event over 6 months before enrollment 
in one of two different dietary models (a Mediterranean 
(MED) diet and a low-fat (LF) diet) over a period of 7 years 
[20]. Treatment of CHD highly depends on any patient’s 
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characteristics. Lifestyle management, with a healthy diet, 
exercise and tobacco avoiding is crucial. Main family drugs 
usually used include: cholesterol-modifying medications, 
antiagregants, beta-blockers, calcium channel blockers, 
Angiotensin-converting enzyme (ACE) inhibitors and angio-
tensin II receptor blockers (ARBs), and Nitroglycerin as a 
rescue drug.
The patients were recruited between November 2009 and 
February 2012, mostly at the Reina Sofia University Hospital 
(Cordoba, Spain), but other health centers from the Cordoba 
and Jaen provinces were also included. The eligibility crite-
ria, design and methods of the CORDIOPREV clinical trial 
have been reported elsewhere [20]. In summary, patients 
were eligible if they were aged between 20 and 75 years, had 
established CHD without clinical events in the last 6 months, 
were asked to follow a long-term dietary intervention and 
did not have severe diseases or an estimated life expectancy 
of less than 5 years. All patients gave their written informed 
consent to participate in the study. The trial protocol and all 
amendments were approved by the local ethic committees, 
following the Helsinki declaration and good clinical prac-
tices. The experimental protocol conformed to international 
ethical standards.
We included patients (462 out of 1002) who had not been 
diagnosed with T2DM at the beginning of the CORDIO-
PREV study, according to the American Diabetes Asso-
ciation (ADA) T2DM diagnosis criteria [21]. From a total 
of 462 patients who did not have a T2DM diagnosis at the 
beginning of the study, 3 patients were excluded from the 
study because we did not have their plasma fatty acid data 
due to technical difficulties in the analytical procedure. Fur-
thermore, of these 459 patients, who had not been clinically 
diagnosed with T2DM at the study baseline, 107 patients 
developed T2DM, according to the ADA diagnosis crite-
ria, after a median follow-up of 60 months. The incidence 
of T2DM was assessed every year according to the ADA 
T2DM criteria: fasting plasma glucose ≥ 126 mg/dL or 2 h 
plasma glucose in the 75 g OGTT ≥ 200 mg/dL or HbA1c 
levels ≥ 6.5%. The baseline characteristics of the subjects in 
the study are shown in Supplementary Table 1.
Study design
The study design has been previously described [20, 22]. 
Briefly, participants were randomized to receive two diets: a 
MED diet or an LF diet. The LF diet consisted of < 30% total 
fat (< 10% saturated fat, 1214% monounsaturated fatty acids 
(MUFA) fat, and 6–8% polyunsaturated fatty acids (PUFA) 
fat), 15% protein, and a minimum of 55% carbohydrates. 
The MED diet comprised a minimum 35% of calories as 
fat (22% MUFA fat, 6% PUFA fat, and < 10% saturated fat), 
15% proteins, and a maximum of 50% carbohydrates. In both 
diets, the cholesterol content was adjusted to < 300 mg/d.
Dietary assessment
At the beginning of the study and every year, each patient 
had a face-to-face interview with a nutritionist to fill in a 
137-item semi-quantitative food frequency questionnaire, 
validated for Spain [23], and well as a validated 14-item 
questionnaire of adherence to the Mediterranean diet to 
produce a Mediterranean diet score [24]. MED and LF 
diets were designed to provide a wide variety of foods, 
including vegetables, fruit, cereals, potatoes, legumes, 
dairy products, meat and fish. Participants in both inter-
vention groups received the same intensive dietary coun-
seling. Nutritionists administered personalized individual 
interviews at inclusion and every 6 months, and quarterly 
group education sessions were held with up to 20 par-
ticipants per session and separate sessions for each group.
Clinical plasma parameters
At the beginning of the study and every year, venous blood 
was collected in tubes containing EDTA and used to ana-
lyze the participants’ biochemical variables. Lipid vari-
ables, serum insulin and plasma glucose were determined, 
as previously reported [25].
Oral glucose tolerance test (OGTT)
Before starting the test, the patients had fasted (food/
drugs) for 12 h and were asked to refrain from smok-
ing during the fasting period and from alcohol intake 
during the preceding 7 days. They were also asked to 
avoid strenuous physical activity the day before the test 
was given. At 8:00 a.m., the patients were admitted to 
the laboratory and an OGTT (75 g dextrose monohydrate 
in 250 mL water) was performed with 0, 30, 60, 90, and 
120 min sampling to establish plasma glucose and insu-
lin levels. OGGT were performed during the 5 years of 
follow-up. The OGTT-derived indexes were calculated as 
previously described [25]. Briefly, the Insulin Sensitivity 
Index (ISI = 10.000÷√([fasting plasma glucose × fasting 
plasma insulin] × [mean glucose in OGTT × mean insulin 
in OGTT]), Disposition Index (DI = ISI × [AUC30 min 
insulin/AUC30 min glucose], where AUC30 min is the 
area under the curve between baseline and 30 min of the 
OGTT for insulin (pmol/L) and glucose (mmol/L) meas-
urements, respectively, calculated by the trapezoidal 
method), Hepatic Insulin Resistance Index (HIRI = (fast-
ing plasma insulin × fasting plasma glucose), Homeostatic 
Model Assessment Insulin Resistance (HOMA-IR = [fast-
ing plasma insulin (mU/L) × 20)/(fasting plasma glucose 
(mmol/L) − 3,5)] and Insulinogenic Index (IGI = [plasma 
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insulin at 30  min  −  fasting plasma insulin (mU/L))/
(plasma glucose at 30 min − fasting plasma glucose(mg/
dL)].
GC–MS analysis of plasma fatty acid
Chromatographic separation was carried out by a gas chro-
matograph (Agilent 7890B) coupled to a mass spectrometer 
(Agilent 5977A), using a SPTM 2560 fused silica column 
(100 m × 0.25 mm, 0.25 μm film thickness) from Supelco 
(Bellefonte, PA, USA). The gas chromatography-mass spec-
trometry (GC–MS) analysis was performed according to the 
following conditions: injector temperature, 250 °C; injec-
tion in splitless mode; gas flow, 0.6 mL  min–1 and injection 
volume, 1 μL. The oven temperature was programmed as 
follows: initial temperature 100 °C, hold for 5 min; ramp at 
4 °C  min–1 up to 240 °C, hold for 20 min. The total analysis 
time was 60 min, with 4 additional min necessary for re-
establishing the initial conditions. The single quadrupole 
mass spectrometer was operated in the full scan mode, with 
the instrumental temperatures set at 250, 250, and 180 °C 
for transfer line, source, and quadrupole, respectively. The 
electron energy was set at 70 eV, and the data acquisition 
was carried out in an m/z range from 45 to 750 m/z and with 
a solvent delay for 14.5 min.
Identification and confirmatory analysis of FA
Qualitative Analysis software (version 7.0, Agilent Tech-
nologies, Santa Clara, CA, USA) was used to process the 
data obtained by GC–MS. Treatment of raw data files started 
with the deconvolution of potential molecular features by 
the algorithm included in the software, which consid-
ered all ions exceeding 3000 counts for the absolute area 
parameter. The NIST Mass Spectral Search Program v.11.0 
(NIST, Washington, DC, USA) was used for the spectral 
search (Mainlib and Replib libraries). Tentative identifica-
tion was reported when the correlation between experimen-
tal and database spectra was above 0.85 in normal search 
mode. Confirmatory analysis was carried out by analysis of 
a FAMEs multistandard from Sigma-Aldrich (Supelco 37 
component FAME mix).
Statistical analysis
RStudio and SPSS statistical software (IBM SPSS Statistics 
version 21.0) were used for the statistical analysis of data. 
The normal distribution of variables was assessed using 
the Kolmogorov–Smirnov test. Data are represented as the 
mean ± SEM for continuous variables and as frequencies for 
categorical variables. P values ≤ 0.05 were considered sta-
tistically significant. The statistical differences in the meta-
bolic variables between groups were evaluated by One-way 
ANOVA. Qualitative variables were compared using the 
Chi-square test. A repeated-measures ANOVA test was used 
to determine the statistical differences between indexes dur-
ing the OGTT at baseline and after 5 years of follow-up. The 
post hoc statistical analysis was completed using Bonfer-
roni's multiple comparison tests.
COX analysis
We performed a Cox proportional hazards regression analy-
sis with each one of 24 FA detected. Baseline individual FA 
values were normalized by log-transformation and scaled in 
multiples of 1 standard deviation (SD). In the Cox propor-
tional hazards regression analysis, we looked for independ-
ent variables which were related to variations in the risk 
function of some patients with respect to a specific event 
studied. Therefore, the Cox regression looked for the rela-
tionship between the risk of T2DM development, and the 
plasma fatty acids levels. Moreover, a Cox regression yields 
a hazard ratio, that indicates which patients have a lower or 
higher risk of suffering the event according to the variable 
or variables included in the analysis.
In addition, we performed a random classification of 
patients into two different datasets: the Training set, with 
275 patients (60% of the total) and the Validation set, with 
184 patients (40% of the total). To analyze the association 
of FA with T2DM development, we calculated the Haz-
ard Ratio (HR) of each FA in the Training set, for each SD 
increase in baseline individual FA levels.
Random survival forest
To select FA with a higher predictive power for T2DM, we 
made a preselection in the Training set by applying ran-
dom survival forest (RSF), in combination with a backward 
selection procedure in the training set [26]. RSF utilizes a 
collection of decision trees for prediction and sorts the dif-
ferent variables by their importance according to the time 
of the event, in this case the development of T2DM since 
the beginning of the study. Therefore, RSF is a very use-
ful tool to reduce the number of metabolites in prospective 
cohorts, selecting those metabolites with greater importance 
related to the event of interest of the study. Consequently, 
we can eliminate the fatty acids which do not contribute to 
the T2DM development, and select a model with the lowest 
prediction error, which includes the fatty acids with higher 
predictive power.
Meanwhile, we validated the results obtained in the train-
ing set in the group of patients included for such end in the 
validation set. We used the same random classification of 
patients in the two different datasets: training and validation 
sets, and the baseline individual FA values normalized by 
log-transformation and scaled in multiples of 1 SD.
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Random survival forest‑based FA Score building
We performed a Cox proportional hazards regression analy-
sis with FA selected in the Training set to determine the 
jointly potential use of these FA as an independent predic-
tor of T2DM development. Further, to assess the relation-
ship between plasma FA profile and T2DM development, 
we built a Fatty Acid Score (FA Score) for each patient by 
multiplying the coefficients of a FA, obtained in the previous 
COX analysis performed in the Training set, by its respective 
value and then adding the products obtained for a certain 
patient. Moreover, we created the Score in the Training and 
Validation sets, for the purpose of validate the selection and 
the coefficients obtained in the two previous steps, which 
were only performed in the Training set. Furthermore, we 
classified patients according to the Score generated into 
median, tertiles and quartiles, and performed the COX pro-
portional hazards regression with each one of those varia-
bles. We classified the same population with different cut-off 
points to evaluate the association of the generated FA Score.
Results
Baseline characteristics of the participants
The baseline characteristics of the subjects in the study are 
shown in Supplementary Table 1. We observed that the val-
ues of body mass index (BMI), weight, waist circumference, 
serum triacylglycerols (TAG), HbA1c, fasting glucose, fast-
ing insulin and HOMA-IR were higher, and the ISI, IGI and 
DI values were lower in the Incident-DIAB group compared 
with the Non-DIAB group (all, p < 0.05).
Individual FA plasma levels as a predictor of T2DM 
development
We performed a Cox proportional hazards regression analy-
sis to determine the potential association of individual fatty 
acids (FA) and type 2 diabetes (T2DM) development. To do 
this, we calculated the Hazard Ratio (HR) for each standard 
deviation (SD) increase in baseline individual FA levels in 
the Training set. Once performed, the analysis was adjusted 
by age, gender, diet consumed, BMI, treatment with statins, 
HDL-c and TAG plasma levels, on the basis that these vari-
ables are considered risk factors for T2DM development and 
statins are diabetogenic, in addition to the adjustment for 
diet as patients consumed a LF diet or the Med diet. (Sup-
plementary Table 2).
From the Cox proportional hazards regression analysis 
of 24 FA detected, 2 of them showed a statistically sig-
nificant association with T2DM development, α-linolenic 
acid (ALA) (18:3n-3) and arachidonic acid (AA) (20:4n-6). 
Regarding ALA, we observed an unadjusted HR of 0.74 
(95% CI 0.57–0.96) and an adjusted HR of 0.73 (95% CI 
0.55–0.97), and for AA an unadjusted HR of 1.23 (95% CI 
0.95–1.61) and an adjusted HR of 1.35 (95% CI 1.02–1.81), 
for each SD increase.
In addition, patients were categorized in ascending ter-
tiles by levels of these fatty acids, ALA and AA (Supple-
mentary Fig. 1), in the Training and Validation set. When 
we categorized our population according to ALA levels we 
observed a lower risk in patients with Intermediate (unad-
justed HR: 0.48; 95% CI 0.26–0.88, and adjusted HR: 0.42; 
95% CI 0.22–0.82), and Higher (unadjusted HR: 0.55; 95% 
CI 0.30–1.00, and adjusted HR: 0.56; 95% CI 0.30–1.07) 
values of ALA in the Training set, whereas in the Valida-
tion set, we obtained similar results, but not significant in 
the patients with Intermediate (unadjusted HR: 0.52; 95% 
CI 0.26–1.06, and adjusted HR: 0.62; 95% CI 0.30–1.31) 
and Higher (unadjusted HR: 0.56; 95% CI 0.28–1.14, and 
adjusted HR: 0.61; 95% CI 0.29–1.29) levels of ALA, taken 
subjects with lower ALA levels as reference.
On the other hand, when patients were classified by AA 
concentration, we did not obtain significant results either in 
Training or Validation. In the Training set, we had a higher 
HR in patients with Intermediate (unadjusted HR: 1.72; 95% 
CI 0.91–3.27, and adjusted HR: 1.91; 95% CI 0.98–3.74) 
and Higher (unadjusted HR: 1.52; 95% CI 0.77–2.92, and 
adjusted HR: 1.74; 95% CI 0.85–3.55) levels of AA, while in 
Validation Set, we observed a slightly higher HR in patients 
with Intermediate (unadjusted HR: 1.46; 95% CI 0.72–2.96, 
and adjusted HR: 1.46; 95% CI 0.69–3.08), and no differ-
ences in subjects with Higher (unadjusted HR: 0.96; 95% 
CI 0.44–2.06, and adjusted HR: 1.02; 95% CI 0.44–2.34) 
values of AA, compared with patients with lower AA 
concentration.
Random survival forest
We performed a random survival forest (RSF) in combina-
tion with a backward selection procedure in the Training set 
to select the FA with a higher predictive power for T2DM 
development and a minimum prediction error (Fig. 1). From 
a total of 24 fatty acids, 4 fatty acids were selected by RSF 
and included in the model with a lower prediction error: 
myristic acid (MA) (14:0), petroselinic acid (PA) (18:1n-
12), α-linolenic acid (ALA) (18:3n-3) and arachidonic acid 
(AA) (20:4n-6).
Association between RSF‑selected fatty acids 
and T2DM development by COX regression analysis
Furthermore, to establish the relationship of the selected 
fatty acids jointly with the development of diabetes, Cox 
proportional hazards regression analysis was performed 
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with these fatty acids together in the Training set (Table 1). 
Once performed, the analysis was adjusted by age, gender, 
diet, BMI, treatment with statins, HDL-c and TAG plasma 
levels, on the basis that these variables are considered risk 
factors for T2DM development and statins are diabetogenic, 
in addition to the adjustment for diet as patients consumed a 
LF diet or the Med diet. The HR obtained for these FA, per 
SD increase, were as follows: for MA, we found an unad-
justed HR of 1.09 (95% CI 0.82–1.46) and an adjusted HR 
of 1.08 (95% CI 0.77–1.52); for PA an unadjusted HR of 
0.93 (95% CI 0.74–1.15) and an adjusted HR of 0.97 (95% 
CI 0.70–1.35); for ALA, we obtained an unadjusted HR of 
0.76 (95% CI 0.59–0.99) and an adjusted HR of 0.76 (95% 
CI 0.57–1.01); and finally, for AA we found an unadjusted 
HR of 1.24 (95% CI 0.91–1.68) and an adjusted HR of 1.34 
(95% CI 0.97–1.88). In summary, when we analyzed the four 
FA selected together, we observed that two were directly 
associated with T2DM development: MA and ARA; mean-
while, PA and ALA were associated with a lower risk of 
T2DM, with ALA the fatty acid with the highest weight in 
the model.
A FA profile‑based score associated with T2DM 
development
We built a Fatty Acid Score (FA Score) to assess the rela-
tionship between the FA profile associated with T2DM 
(RSF-selected fatty acid) and the development of this dis-
ease (see Materials and Methods). We next performed a 
COX proportional hazards regression analysis, and once 
performed, adjusted it by age, gender, diet, BMI, treat-
ment with statins, HDL-c and TAG plasma levels, to test 
the T2DM risk according to the FA Score generated. We 
found an unadjusted HR of 2.72 (95% CI 2.14–3.45) and an 
adjusted HR of 3.15 (95% CI 2.04–3.37) in the Training set, 
while in the Validation set we obtained an unadjusted HR of 
2.30 (95% CI 1.62–3.20) and an adjusted HR of 2.14 (95% 
CI 1.50–2.84), per standard deviation unit.
Furthermore, we classified patients according to the score 
generated by ascending tertiles, quartiles and median and 
evaluated the association between the FA Score and T2D 
development by COX proportional hazards regression, in 
the Training and in the Validation set, separately. The dif-
ferent cutoff points were done for the purpose of evaluating 
the association between the development of T2DM and the 
generated FA Score.
In the Training set (Fig.  2), when we classified the 
patients by tertiles of the FA Score, we observed that patients 
classified in the Intermediate (unadjusted HR: 1.93; 95% 
CI 0.98–3.79, and adjusted HR: 2.13; 95% CI 1.03–4.42,) 
and Higher (unadjusted HR: 2.08; 95% CI 1.06–4.07, and 
adjusted HR: 2.36; 95% CI 1.11–5.00) FA Score groups, 
showed a greater risk of T2DM development than patients 
categorized with a Lower FA Score group, which was the 
reference group. The second classification by quartiles of 
the FA Score yielded consistent results, showing that the 
patients classified in the Higher FA Score (unadjusted HR: 
2.16; 95% CI 1.04–4.48, and adjusted HR: 2.59; 95% CI 
1.14–5.88) had a higher risk of diabetes development, taking 
the Lower FA Score group as reference, and intermediate 
results in the other two groups. Finally, we performed a third 
categorization of the patients by medians of the FA Score, 
and we observed an increased risk of T2DM development 
for patients in the Higher FA Score group (unadjusted HR: 
1.63; 95% CI 0.97–2.71, and adjusted HR: 1.65; 95% CI 
0.94–2.89) compared with the Lower FA Score group.
Fig. 1  Selection of the best 
model by Random Survival 
Forest (RSF). Selection in the 
Training set of fatty acids with a 
higher predictive power for type 
2 diabetes, by applying an RSF 
in combination with a backward 
selection procedure
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In contrast, in the Validation set (Fig. 3), when patients 
were categorized by tertiles of FA Score, the Higher FA 
Score (unadjusted HR: 2.71; 95% CI 1.25–5.85, and adjusted 
HR: 3.19; 95% CI 1.37–7.43) showed a higher risk of T2DM 
development, taking the Lower FA Score group as reference. 
Similarly, regarding the second classification by quartiles, 
patients in the Higher FA Score (unadjusted HR: 2.14; 95% 
CI 0.92–4.95, and adjusted HR: 2.32; 95% CI 0.94–5.69) 
showed a greater T2DM risk compared with subjects in the 
Lower Score group, with intermediate results in the other 
two groups. Along the same lines, when patients were cat-
egorized by medians, we observed that patients in the Higher 
FA Score group had a higher risk (unadjusted HR: 2.14; 95% 
CI 1.15–3.98, and adjusted HR: 2.18; 95% CI 1.13–4.18) 
compared to the Lower FA Score group.
Relationship between FA profile and insulin 
resistance and beta‑cell functionality indexes
We also evaluated insulin resistance and beta-cell function 
as assessed by validated indexes during 5 years of follow-up 
in the patients, which were categorized by ascending tertiles 
of the FA Score, which represent the FA profile associated to 
T2DM, and also by plasma levels of FA selected in the RSF 
(Fig. 4). When we classified our population according to the 
FA Score, we observed that patients included in the Low 
FA Score group presented higher ISI levels than patients in 
the High FA Score group (p = 0.009), and lower values of 
HIRI than patients classified in the Intermediate and High 
FA Score groups (p = 0.036 and p = 0.003, respectively), 
during the follow-up period.
Regarding the results of the patients classified by levels of 
PA, we observed that patients with low levels of PA had lower 
values of ISI than patients with intermediate levels of this FA 
(p = 0.038). When we categorized patients according to the 
ALA we found that patients with a lower ALA concentration 
presented lower ISI and higher HIRI values than patients who 
had a higher concentration (p = 0.044 and p = 0.047, respec-
tively), during the follow-up period.
Discussion
In our study, we identified a fatty acids (FA) profile in 
patients with CHD to assess the T2DM development risk by 
Random Survival Forest, a decision tree for prediction which 
sorted the different fatty acids by their importance accord-
ing to the time of the T2DM development, and reduced the 
number of variables to 4 fatty acids from a total of 24 FA 
identified in plasma. Further testing in a Validation set of 
patients yielded reproducible results. Moreover, patients 
with a deleterious FA profile (higher FA Score values) have 
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higher hepatic insulin resistance, as determined by the HIRI 
index.
Several studies have shown the relationship between the 
individual abundance of plasma FA and T2DM [13, 14]. In 
addition, an altered FA composition has also been related 
with insulin resistance [27]. Moreover, in terms of specific 
FA, it has been proposed that the different polyunsaturated 
fatty acids (PUFA), both those from plant- and marine ori-
gins, play a potentially beneficial role, although there is 
also a good deal of controversy. For example, the beneficial 
role of n3 PUFAs has been postulated for the prevention of 
metabolic syndrome or T2DM, but there is no conclusive 
evidence, and some studies have shown a lack of significant 
effect of n3 PUFA on glycemic control or insulin sensitiv-
ity [28, 29]. In our study, we found an inverse association 
between the plant-based essential n3 PUFA α-linolenic acid 
(ALA), the precursor of all n3 fatty acids [30], and the risk 
of T2DM development, whereas marine-based n3 PUFAs, 
such as eicosapentaenoic acid (EPA) or docosahexaenoic 
acid (DHA) were not selected in the model. However, some 
studies support the beneficial role of fish oil supplementation 
in T2DM prevention [31]. Our findings in the coronary heart 
Fig. 2  Disease-free survival 
by COX proportional hazards 
regression analysis according 
to FA Score in the Training 
set. Patients from the Training 
set were categorized accord-
ing to the FA Score by tertiles, 
quartiles and median (ascend-
ing order). *This model was 
adjusted for age, gender, BMI, 
diet, treatment with statins, 
HDL-c and TG plasma levels. 
The hazard ratio (HR) between 
groups was calculated
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disease population from the CORDIOPREV study are in line 
with previously reported findings from the study of EPIC-
InterAct in a general population, which showed that ALA 
has a strong inverse association with T2DM risk, and that 
there is no association between the marine origin n3 PUFAs, 
EPA and DHA, and T2DM development [32]. Moreover, 
the relationship between plasma ALA levels and T2DM is 
supported by both animal and in vitro studies, which have 
demonstrated the capacity of ALA to regulate glucose home-
ostasis by affecting insulin sensitivity in different ways, such 
as potential functions in gene regulation, or fat metabolism 
[33–36]. However, human studies monitoring ALA intake 
have also yielded controversial results: whereas some stud-
ies have reported moderately improved fasting plasma glu-
cose and markers of insulin resistance [37, 38], others have 
not shown this effect [28, 39, 40], probably because plasma 
levels reflect the real intake of FA more accurately than the 
nutritional surveys used in previous studies monitoring ALA 
intake. In this context, our study, in which we determined 
the full plasma FA composition, plasma ALA accurately 
assessed the T2DM risk and was also associated with insulin 
action. In fact, patients with higher levels of ALA showed 
Fig. 3  Disease-free survival 
by COX proportional hazards 
regression analysis according 
to FA Score in the Validation 
set. Patients from the Validation 
set were categorized accord-
ing to the FA Score by tertiles, 
quartiles and median (ascend-
ing order). *This model was 
adjusted for age, gender, BMI, 
diet, treatment with statins, 
HDL-c and TG plasma levels. 
The hazard ratio (HR) between 
groups was calculated
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better insulin sensitivity, with a lower insulin resistance and 
lower hepatic insulin resistance.
In addition to the ALA, an even-chain saturated FA, 
myristic acid (MA), an n6 PUFA, arachidonic acid (AA), 
and petroselinic acid (PA) were jointly selected by random 
survival forest in the model with the lowest error prediction 
to assess T2DM development.
In line with this, the mechanism linking T2DM and the 
n6 PUFA has not yet been clarified, and their proposed 
beneficial/deleterious effects have not been definitively 
proven and may depend on a complex interplay of meta-
bolic factors [41]. In this context, γ-linolenic acid (GLA) 
has been described as a possible adjuvant in the prevention 
of T2DM [42], while other works have shown that elevated 
levels the GLA and its elongation product, the dihomo-
γ-linolenic (DGLA), are associated with higher T2DM 
incidence [32]. However, in our study with coronary heart 
disease patients, neither of these two n6 PUFA showed a 
significant association with T2DM development. The most 
representative n6 PUFA in plasma phospholipids, arachi-
donic acid (AA), can be derived through the exogenous 
intake, since various foods are a source of AA for humans, 
such as lean meat and meat fats or eggs, or from linoleic 
acid (LA), an essential n6 fatty acid mainly found in vege-
table oils. Previous works that have studied the relationship 
between levels of AA and T2DM yielded contradictory 
results [16, 43]. Here, our study showed that individually, 
as well as being a contributor to the FA profile identified, 
AA plasma levels contribute towards increasing the T2DM 
risk. This deleterious effect may be due to the fact that 
AA can be converted during the inflammatory cascade 
to pro-inflammatory eicosanoids, such as prostaglandins, 
thromboxanes or leukotrienes, which in large quantities 
contribute to inflammatory disorders and the formation of 
atheromas [44, 45] and other inflammation-related disor-
ders such as T2DM, as the activation of inflammatory path-
ways has been causally linked to insulin-resistance [46]. 
In addition, the elevated levels of the rare and uncommon 
petroselinic acid (PA) in low-risk patients, which can, in 
turn, inhibit AA synthesis [47], suggests an overall protec-
tive role of PA against inflammation, and a preventive role 
for T2DM development.
Regarding MA, this FA can be derived from both exog-
enous intake, since it is widely distributed among plant and 
animal fats like butter or palm oil [48], and endogenous 
synthesis, being a minor product of de novo lipogenesis 
[49]. Our results are in line with previous works which have 
already shown that higher MA levels are positively associ-
ated with incident type 2 diabetes [13, 14, 50]. Moreover, 
the relationship between MA and diabetes risk seems to be 
independent of the patients’ insulin sensitivity or insulin 
release [50], which is in line with our results, as we did not 
find differences between levels of MA and insulin resistance 
or beta-cell functionality indexes.
Overall, the effect of plasma FA composition on T2DM 
development remains disputed and its roles are not still com-
pletely understood, which is partial because, most of the 
time, FA contribution is assessed individually or by sub-
classes, such as n6 or n3 fatty acids [32, 51]. To test the pos-
sibility of defining a fatty acid profile associated with T2DM 
development, we built a FA Score based on the contribution 
of several FA together, selected by RSF, and obtained an 
accurate prediction, which also increased after adjustment 
with co-variables. In fact, due to the complexity of the cur-
rent diets, the FA are not consumed in an isolated way, but 
in combination with other FA through the nutrients, which 
is why we built an FA Score based on the selected plasma 
FA of the whole profile, and not by subclasses or individual 
fatty acids, thus improving the risk assessment of the FA 
individually. Furthermore, patients who had a deleterious FA 
profile (higher FA Score values) presented impaired insulin 
sensitivity, with higher insulin resistance and higher hepatic 
insulin resistance, which showed a relationship between an 
altered fatty acid profile and insulin sensitivity [27].
Our results also indicate that the identification of a 
defined fatty acid profile associated with T2DM develop-
ment improves the prediction of the risk of its development 
as compared with the Finnish Diabetes Risk Score (FIND-
RISC) [52], a diabetes risk score based on anthropometric 
measures, blood pressure, physical activity and dietary hab-
its, as can be seen in a previous work in which we assessed 
the T2DM risk to this same population [53]. Although the 
predictive power of this model was relatively high, the fact 
that several parameters are not specific for T2DM and/or are 
self-reported, diminishes the reliability and specificity for 
the prediction of T2DM status. In fact, our work highlights 
the need to identify novel biomarkers for the early detection 
of T2DM risk and/or better prognosis of T2D and to assess 
the efficacy of targeted interventions.
Certain limitations of the current study must be men-
tioned. One limitation lies in the fact that this research is 
based on a long-term, well-controlled dietary intervention, 
which ensures the quality of the study but may not reflect 
the level of compliance in a free-living population. Another 
limitation lies in the fact that the prevention of T2DM was 
Fig. 4  Relationship between FA profile and insulin resistance and 
beta-cell functionality indexes. Patients were categorized by baseline 
concentration of MA, PA, ALA and AA, and by FA Score calculated 
(ascending order). Mean ± S.E.M. of the insulin-sensitive index (ISI), 
disposition index (DI) and hepatic insulin resistance index (HIRI) 
during the follow-up period. ANOVA for repeated measures p-val-
ues adjusted by age, gender, BMI, diet, HDL-c and TG plasma lev-
els. Global p-values: P(t): time effect; P(g): group effect; P(i): time 
by group interaction. Different letters indicate significant differences 
(p < 0.05) between groups in the Post-hoc Bonferroni's multiple com-
parison tests
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not the primary endpoint of the CORDIOPREV trial but 
was rather a secondary analysis conducted in the subgroup 
of cardiovascular patients without T2DM at baseline. In fact, 
the study included a large number of patients with acute 
myocardial infarction, which limits our findings to people 
with these characteristics and precludes its generalization 
to healthy individuals.
In conclusion, our results suggest that an altered fatty acid 
profile precedes T2DM development and may be used as a 
predictive biomarker for the detection of patients at risk of 
T2DM development. In addition, our results also support 
the association between plasma lipid quantity and quality 
and insulin sensitivity, based on the relationship between a 
defined fatty acid profile, combined as a FA Score, and indi-
vidual FA plasma levels with insulin sensitivity assessing 
indexes. Further studies are needed to assess the effective-
ness of nutritional intervention in changing the FA profile 
and, therefore, preventing the development of type 2 diabetes 
mellitus.
Supplementary Information The online version contains supplemen-
tary material available at https:// doi. org/ 10. 1007/ s00394- 021- 02676-z.
Acknowledgements The CIBEROBN is an initiative of the Instituto de 
Salud Carlos III, Madrid, Spain. We would like to thank the Córdoba 
branch of the Biobank of the Sistema Sanitario Público de Andalucía 
(Andalusia, Spain) for providing the biological human samples. We 
would also like to thank the EASP (Escuela Andaluza de Salud Pub-
lica), Granada, Spain, which performed the randomization process for 
this study.
Author contributions AV-G and JFA-D contributed equally to this 
work. AC and JL-M contributed equally to this work. The authors’ 
responsibilities were as follows: AV-G, JFA-D, CV-d, APA, MPC, and 
JLR-C collected the data; JD-L, MMM, PP-M, MBS, AC, and JLM 
designed and conducted the research and provided materials or partici-
pants; AV-G, JFA-D, CV-D, FR-C, and JD-L analysed the data; AV-G 
and JFA-D wrote the manuscript; JD-L, MMM, PP-M, MBS, and AC 
provided significant advice and support in reviewing the drafting of the 
manuscript; MBS, AC, and JLM had the main responsibility for the 
final content. All the authors read and approved the final manuscript. 
All authors critically reviewed and revised the report and have read and 
approved the final version.
Funding Open Access funding provided thanks to the CRUE-CSIC 
agreement with Springer Nature. The CIBEROBN is an initiative of 
the Instituto de Salud Carlos III, Madrid, Spain. The CORDIOPREV 
study is supported by the Ministerio de Economía y Competitividad 
(AGL2012/39615, PCIN-2016-084, PIE14/00005, and PIE14/00031 
to J L-M; AGL2015-67896-P to J L-M and A C; CP14/00114 to A 
C; DTS19/00007 to A C; FIS PI13/00023 to J D-L, PI19/00299 to 
AC; PI16/01777 to F P-J and P P-M); Fundación Patrimonio Comu-
nal Olivarero, Junta de Andalucía (Consejería de Salud, Consejería de 
Agricultura y Pesca, Consejería de Innovación, Ciencia y Empresa), 
Diputaciones de Jaén y Córdoba, Centro de Excelencia en Investigación 
sobre Aceite de Oliva y Salud and Ministerio de Medio Ambiente, 
Medio Rural y Marino, Gobierno de España; Consejería de Innovación, 
Ciencia y Empresa, Proyectos de Investigación de Excelencia, Junta 
de Andalucía (CVI-7450 to J L-M); and by the Fondo Europeo de 
Desarrollo Regional (FEDER). This study was also partially funded by 
the European Commission and national funding partners of the Joint 
Programming Initiative A Healthy Diet for a Healthy Life, within the 
ERA-HDHL cofounded joint call Biomarkers for Nutrition and Health. 
Antonio Camargo is supported by an ISCIII research contract (Pro-
grama Miguel-Servet CP14/00114 and CPII19/00007). JMO is sup-
ported by the US Department of Agriculture, under agreement no. 
8050-51000-098-00D. We wish to thank the Córdoba branch of the 
Biobank of the Sistema Sanitario Público de Andalucía (Andalusia, 
Spain) for providing the human biological samples. We would also 
like to thank the EASP (Escuela Andaluza de Salud Publica), Granada, 
Spain, which performed the randomization process for this study. Fund-
ing for open access charge: Universidad de Córdoba/CBUA.
Availability of data and material There are restrictions on the availabil-
ity of data for the CORDIOPREV study, due to confidentiality policies. 
The CORDIOPREV study is an ongoing study and, therefore, databases 
are currently not available. After the completion of CORDIOPREV 
study, the datasets used and/or analysed during the current study will 
be available from the corresponding author on request, within reason.
Code availability Not applicable.
Declarations 
Conflict of interest The author reports no conflicts of interest in this 
work.
Ethical approval The trial protocol and amendments were approved by 
the local ethics committee of Reina Sofia University Hospital in Cor-
doba, following the Helsinki declaration and good clinical practices.
Consent to participate All the patients gave written, informed consent 
to participate in the study.
Consent for publication Not applicable.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article's Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article's Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.
References
 1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnen-
kamp U, Shaw JE (2014) Global estimates of diabetes preva-
lence for 2013 and projections for 2035. Diabetes Res Clin Pract 
103(2):137–149. https:// doi. org/ 10. 1016/j. diabr es. 2013. 11. 002
 2. Guasch-Ferre M, Becerra-Tomas N, Ruiz-Canela M, Corella D, 
Schroder H, Estruch R, Ros E, Aros F, Gomez-Gracia E, Fiol M, 
Serra-Majem L, Lapetra J, Basora J, Martin-Calvo N, Portoles 
O, Fito M, Hu FB, Forga L, Salas-Salvado J (2017) Total and 
subtypes of dietary fat intake and risk of type 2 diabetes mellitus 
in the Prevencion con Dieta Mediterranea (PREDIMED) study. 
European Journal of Nutrition 
1 3
Am J Clin Nutr 105(3):723–735. https:// doi. org/ 10. 3945/ ajcn. 116. 
142034
 3. Einarson TR, Acs A, Ludwig C, Panton UH (2018) Prevalence 
of cardiovascular disease in type 2 diabetes: a systematic litera-
ture review of scientific evidence from across the world in 2007–
2017. Cardiovasc Diabetol 17(1):83. https:// doi. org/ 10. 1186/ 
s12933- 018- 0728-6
 4. Defronzo RA (2010) Insulin resistance, lipotoxicity, type 2 dia-
betes and atherosclerosis: the missing links. The Claude Bernard 
Lecture 2009. Diabetologia 53(7):1270–1287. https:// doi. org/ 10. 
1007/ s00125- 010- 1684-1
 5. Kolb H, Martin S (2017) Environmental/lifestyle factors in 
the pathogenesis and prevention of type 2 diabetes. BMC Med 
15(1):131. https:// doi. org/ 10. 1186/ s12916- 017- 0901-x
 6. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, 
Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louher-
anta A, Rastas M, Salminen V, Uusitupa M (2001) Prevention of 
type 2 diabetes mellitus by changes in lifestyle among subjects 
with impaired glucose tolerance. N Engl J Med 344(18):1343–
1350. https:// doi. org/ 10. 1056/ nejm2 00105 03344 1801
 7. Salas-Salvado J, Bullo M, Babio N, Martinez-Gonzalez MA, 
Ibarrola-Jurado N, Basora J, Estruch R, Covas MI, Corella D, 
Aros F, Ruiz-Gutierrez V, Ros E (2011) Reduction in the inci-
dence of type 2 diabetes with the Mediterranean diet: results of 
the PREDIMED-Reus nutrition intervention randomized trial. 
Diabetes Care 34(1):14–19. https:// doi. org/ 10. 2337/ dc10- 1288
 8. American Diabetes Association (2014) Standards of medical care 
in diabetes. Diabetes Care 37(Suppl 1):S14–80. https:// doi. org/ 10. 
2337/ dc14- S014
 9. Forouhi NG, Misra A, Mohan V, Taylor R, Yancy W (2018) Die-
tary and nutritional approaches for prevention and management 
of type 2 diabetes. BMJ (Clin Res ed) 361:k2234. https:// doi. org/ 
10. 1136/ bmj. k2234
 10. Razquin C, Toledo E, Clish CB, Ruiz-Canela M, Dennis C, 
Corella D, Papandreou C, Ros E, Estruch R, Guasch-Ferre M, 
Gomez-Gracia E, Fito M, Yu E, Lapetra J, Wang D, Romaguera 
D, Liang L, Alonso-Gomez A, Deik A, Bullo M, Serra-Majem L, 
Salas-Salvado J, Hu FB, Martinez-Gonzalez MA (2018) Plasma 
Lipidomic profiling and risk of type 2 diabetes in the PREDIMED 
trial. Diabetes Care 41(12):2617–2624. https:// doi. org/ 10. 2337/ 
dc18- 0840
 11. Razquin C, Liang L, Toledo E, Clish CB, Ruiz-Canela M, Zheng 
Y, Wang DD, Corella D, Castaner O, Ros E, Aros F, Gomez-
Gracia E, Fiol M, Santos-Lozano JM, Guasch-Ferre M, Serra-
Majem L, Sala-Vila A, Buil-Cosiales P, Bullo M, Fito M, Portoles 
O, Estruch R, Salas-Salvado J, Hu FB, Martinez-Gonzalez MA 
(2018) Plasma lipidome patterns associated with cardiovascular 
risk in the PREDIMED trial: a case-cohort study. Int J Cardiol 
253:126–132. https:// doi. org/ 10. 1016/j. ijcard. 2017. 10. 026
 12. Imamura F, Sharp SJ, Koulman A, Schulze MB, Kroger J, Griffin 
JL, Huerta JM, Guevara M, Sluijs I, Agudo A, Ardanaz E, Balkau 
B, Boeing H, Chajes V, Dahm CC, Dow C, Fagherazzi G, Feskens 
EJM, Franks PW, Gavrila D, Gunter M, Kaaks R, Key TJ, Khaw 
KT, Kuhn T, Melander O, Molina-Portillo E, Nilsson PM, Olsen 
A, Overvad K, Palli D, Panico S, Rolandsson O, Sieri S, Sacer-
dote C, Slimani N, Spijkerman AMW, Tjonneland A, Tumino 
R, van der Schouw YT, Langenberg C, Riboli E, Forouhi NG, 
Wareham NJ (2017) A combination of plasma phospholipid fatty 
acids and its association with incidence of type 2 diabetes: The 
EPIC-InterAct case-cohort study. PLoS Med 14(10):e1002409. 
https:// doi. org/ 10. 1371/ journ al. pmed. 10024 09
 13. Huang L, Lin JS, Aris IM, Yang G, Chen WQ, Li LJ (2019) Cir-
culating saturated fatty acids and incident type 2 diabetes: a sys-
tematic review and meta-analysis. Nutrients 11:5. https:// doi. org/ 
10. 3390/ nu110 50998
 14. Forouhi NG, Koulman A, Sharp SJ, Imamura F, Kröger J, 
Schulze MB, Crowe FL, Huerta JM, Guevara M, Beulens JW, 
van Woudenbergh GJ, Wang L, Summerhill K, Griffin JL, Feskens 
EJ, Amiano P, Boeing H, Clavel-Chapelon F, Dartois L, Fagher-
azzi G, Franks PW, Gonzalez C, Jakobsen MU, Kaaks R, Key TJ, 
Khaw KT, Kühn T, Mattiello A, Nilsson PM, Overvad K, Pala 
V, Palli D, Quirós JR, Rolandsson O, Roswall N, Sacerdote C, 
Sánchez MJ, Slimani N, Spijkerman AM, Tjonneland A, Tormo 
MJ, Tumino R, van der AD, van der Schouw YT, Langenberg C, 
Riboli E, Wareham NJ, (2014) Differences in the prospective asso-
ciation between individual plasma phospholipid saturated fatty 
acids and incident type 2 diabetes: the EPIC-InterAct case-cohort 
study. Lancet Diabetes Endocrinol 2(10):810–818. https:// doi. org/ 
10. 1016/ s2213- 8587(14) 70146-9
 15. Abbott KA, Burrows TL, Thota RN, Acharya S, Garg ML (2016) 
Do ω-3 PUFAs affect insulin resistance in a sex-specific manner? 
A systematic review and meta-analysis of randomized controlled 
trials. Am J Clin Nutr 104(5):1470–1484. https:// doi. org/ 10. 3945/ 
ajcn. 116. 138172
 16. Wu JHY, Marklund M, Imamura F, Tintle N, Ardisson Korat AV, 
de Goede J, Zhou X, Yang WS, de Oliveira Otto MC, Kröger J, 
Qureshi W, Virtanen JK, Bassett JK, Frazier-Wood AC, Lankinen 
M, Murphy RA, Rajaobelina K, Del Gobbo LC, Forouhi NG, 
Luben R, Khaw KT, Wareham N, Kalsbeek A, Veenstra J, Luo 
J, Hu FB, Lin HJ, Siscovick DS, Boeing H, Chen TA, Steffen B, 
Steffen LM, Hodge A, Eriksdottir G, Smith AV, Gudnason V, 
Harris TB, Brouwer IA, Berr C, Helmer C, Samieri C, Laakso 
M, Tsai MY, Giles GG, Nurmi T, Wagenknecht L, Schulze MB, 
Lemaitre RN, Chien KL, Soedamah-Muthu SS, Geleijnse JM, Sun 
Q, Harris WS, Lind L, Ärnlöv J, Riserus U, Micha R, Mozaffar-
ian D (2017) Omega-6 fatty acid biomarkers and incident type 2 
diabetes: pooled analysis of individual-level data for 39 740 adults 
from 20 prospective cohort studies. Lancet Diabetes Endocrinol 
5(12):965–974. https:// doi. org/ 10. 1016/ s2213- 8587(17) 30307-8
 17. Zheng JS, Huang T, Yang J, Fu YQ, Li D (2012) Marine N-3 poly-
unsaturated fatty acids are inversely associated with risk of type 2 
diabetes in Asians: a systematic review and meta-analysis. PLoS 
ONE 7(9):e44525. https:// doi. org/ 10. 1371/ journ al. pone. 00445 25
 18. Sampath H, Ntambi JM (2005) Polyunsaturated fatty acid regula-
tion of genes of lipid metabolism. Annu Rev Nutr 25:317–340. 
https:// doi. org/ 10. 1146/ annur ev. nutr. 25. 051804. 101917
 19. Fessler MB, Rudel LL, Brown JM (2009) Toll-like receptor sign-
aling links dietary fatty acids to the metabolic syndrome. Curr 
Opin Lipidol 20(5):379–385. https:// doi. org/ 10. 1097/ MOL. 0b013 
e3283 2fa5c4
 20. Delgado-Lista J, Perez-Martinez P, Garcia-Rios A, Alcala-Diaz 
JF, Perez-Caballero AI, Gomez-Delgado F, Fuentes F, Quintana-
Navarro G, Lopez-Segura F, Ortiz-Morales AM, Delgado-Casado 
N, Yubero-Serrano EM, Camargo A, Marin C, Rodriguez-Can-
talejo F, Gomez-Luna P, Ordovas JM, Lopez-Miranda J, Perez-
Jimenez F (2016) CORonary Diet Intervention with Olive oil and 
cardiovascular PREVention study (the CORDIOPREV study): 
rationale, methods, and baseline characteristics: a clinical trial 
comparing the efficacy of a Mediterranean diet rich in olive 
oil versus a low-fat diet on cardiovascular disease in coronary 
patients. Am Heart J 177:42–50. https:// doi. org/ 10. 1016/j. ahj. 
2016. 04. 011
 21. American Diabetes Association (2011) Diagnosis and classifi-
cation of diabetes mellitus. Diabetes Care 34(Suppl 1):62–69. 
https:// doi. org/ 10. 2337/ dc11- S062
 22. Quintana-Navarro GM, Alcala-Diaz JF, Lopez-Moreno J, Perez-
Corral I, Leon-Acuña A, Torres-Peña JD, Rangel-Zuñiga OA, 
Arenas de Larriva AP, Corina A, Camargo A, Yubero-Serrano 
EM, Rodriguez-Cantalejo F, Garcia-Rios A, Luque RM, Ordovas 
JM, Perez-Martinez P, Lopez-Miranda J, Delgado-Lista J (2020) 
 European Journal of Nutrition
1 3
Long-term dietary adherence and changes in dietary intake in 
coronary patients after intervention with a Mediterranean diet or 
a low-fat diet: the CORDIOPREV randomized trial. Eur J Nutr 
59(5):2099–2110. https:// doi. org/ 10. 1007/ s00394- 019- 02059-5
 23. Fernandez-Ballart JD, Pinol JL, Zazpe I, Corella D, Carrasco P, 
Toledo E, Perez-Bauer M, Martinez-Gonzalez MA, Salas-Salvado 
J, Martin-Moreno JM (2010) Relative validity of a semi-quanti-
tative food-frequency questionnaire in an elderly Mediterranean 
population of Spain. Br J Nutr 103(12):1808–1816. https:// doi. 
org/ 10. 1017/ S0007 11450 99938 37
 24. Martinez-Gonzalez MA, Fernandez-Jarne E, Serrano-Martinez 
M, Wright M, Gomez-Gracia E (2004) Development of a short 
dietary intake questionnaire for the quantitative estimation of 
adherence to a cardioprotective Mediterranean diet. Eur J Clin 
Nutr 58(11):1550–1552. https:// doi. org/ 10. 1038/ sj. ejcn. 16020 04
 25. Blanco-Rojo R, Alcala-Diaz JF, Wopereis S, Perez-Martinez 
P, Quintana-Navarro GM, Marin C, Ordovas JM, van Ommen 
B, Perez-Jimenez F, Delgado-Lista J, Lopez-Miranda J (2015) 
The insulin resistance phenotype (muscle or liver) interacts 
with the type of diet to determine changes in disposition index 
after 2 years of intervention: the CORDIOPREV-DIAB ran-
domised clinical trial. Diabetologia. https:// doi. org/ 10. 1007/ 
s00125- 015- 3776-4
 26. Dietrich S, Floegel A, Troll M, Kuhn T, Rathmann W, Peters A, 
Sookthai D, von Bergen M, Kaaks R, Adamski J, Prehn C, Boeing 
H, Schulze MB, Illig T, Pischon T, Knuppel S, Wang-Sattler R, 
Drogan D (2016) Random Survival Forest in practice: a method 
for modelling complex metabolomics data in time to event analy-
sis. Int J Epidemiol 45(5):1406–1420. https:// doi. org/ 10. 1093/ ije/ 
dyw145
 27. Petersson H, Basu S, Cederholm T, Riserus U (2008) Serum fatty 
acid composition and indices of stearoyl-CoA desaturase activity 
are associated with systemic inflammation: longitudinal analyses 
in middle-aged men. Br J Nutr 99(6):1186–1189. https:// doi. org/ 
10. 1017/ s0007 11450 78716 74
 28. Akinkuolie AO, Ngwa JS, Meigs JB, Djoussé L (2011) Omega-3 
polyunsaturated fatty acid and insulin sensitivity: a meta-analysis 
of randomized controlled trials. Clin Nutr (Edinburgh, Scotland) 
30(6):702–707. https:// doi. org/ 10. 1016/j. clnu. 2011. 08. 013
 29. Hartweg J, Perera R, Montori V, Dinneen S, Neil HA, Farmer A 
(2008) Omega-3 polyunsaturated fatty acids (PUFA) for type 2 
diabetes mellitus. Cochrane Database Syst Rev. https:// doi. org/ 10. 
1002/ 14651 858. CD003 205. pub2
 30. Stark AH, Reifen R, Crawford MA (2016) Past and present 
insights on alpha-linolenic acid and the omega-3 fatty acid fam-
ily. Crit Rev Food Sci Nutr 56(14):2261–2267. https:// doi. org/ 10. 
1080/ 10408 398. 2013. 828678
 31. Gao H, Geng T, Huang T, Zhao Q (2017) Fish oil supplemen-
tation and insulin sensitivity: a systematic review and meta-
analysis. Lipids Health Dis 16(1):131. https:// doi. org/ 10. 1186/ 
s12944- 017- 0528-0
 32. Forouhi NG, Imamura F, Sharp SJ, Koulman A, Schulze MB, Zheng 
J, Ye Z, Sluijs I, Guevara M, Huerta JM, Kroger J, Wang LY, Sum-
merhill K, Griffin JL, Feskens EJ, Affret A, Amiano P, Boeing H, 
Dow C, Fagherazzi G, Franks PW, Gonzalez C, Kaaks R, Key TJ, 
Khaw KT, Kuhn T, Mortensen LM, Nilsson PM, Overvad K, Pala 
V, Palli D, Panico S, Quiros JR, Rodriguez-Barranco M, Rolands-
son O, Sacerdote C, Scalbert A, Slimani N, Spijkerman AM, Tjon-
neland A, Tormo MJ, Tumino R, van der A D, van der Schouw 
YT, Langenberg C, Riboli E, Wareham NJ (2016) Association of 
plasma phospholipid n-3 and n-6 polyunsaturated fatty acids with 
type 2 diabetes: the EPIC-InterAct case-cohort study. PLoS Med 
13(7):e1002094. https:// doi. org/ 10. 1371/ journ al. pmed. 10020 94
 33. Oliveira V, Marinho R, Vitorino D, Santos GA, Moraes JC, Dra-
gano N, Sartori-Cintra A, Pereira L, Catharino RR, da Silva AS, 
Ropelle ER, Pauli JR, De Souza CT, Velloso LA, Cintra DE (2015) 
Diets containing alpha-Linolenic (omega3) or Oleic (omega9) fatty 
acids rescues obese mice from insulin resistance. Endocrinology 
156(11):4033–4046. https:// doi. org/ 10. 1210/ en. 2014- 1880
 34. Ghafoorunissa IA, Natarajan S (2005) Substituting dietary lin-
oleic acid with alpha-linolenic acid improves insulin sensitivity 
in sucrose fed rats. Biochem Biophys Acta 1733(1):67–75. https:// 
doi. org/ 10. 1016/j. bbalip. 2004. 12. 003
 35. Yepuri G, Marcelino H, Shahkhalili Y, Aprikian O, Mace K, Sey-
doux J, Miles JL, Montani JP, Dulloo AG (2011) Dietary modula-
tion of body composition and insulin sensitivity during catch-up 
growth in rats: effects of oils rich in n-6 or n-3 PUFA. Br J Nutr 
105(12):1750–1763. https:// doi. org/ 10. 1017/ s0007 11451 00056 59
 36. Miotto PM, Horbatuk M, Proudfoot R, Matravadia S, Bakovic 
M, Chabowski A, Holloway GP (2017) alpha-Linolenic acid sup-
plementation and exercise training reveal independent and addi-
tive responses on hepatic lipid accumulation in obese rats. Am J 
Physiol Endocrinol Metab 312(6):E461–E470. https:// doi. org/ 10. 
1152/ ajpen do. 00438. 2016
 37. Muramatsu T, Yatsuya H, Toyoshima H, Sasaki S, Li Y, Otsuka 
R, Wada K, Hotta Y, Mitsuhashi H, Matsushita K, Murohara T, 
Tamakoshi K (2010) Higher dietary intake of alpha-linolenic 
acid is associated with lower insulin resistance in middle-aged 
Japanese. Prev Med 50(5–6):272–276. https:// doi. org/ 10. 1016/j. 
ypmed. 2010. 02. 014
 38. Heskey CE, Jaceldo-Siegl K, Sabate J, Fraser G, Rajaram S (2016) 
Adipose tissue alpha-linolenic acid is inversely associated with 
insulin resistance in adults. Am J Clin Nutr 103(4):1105–1110. 
https:// doi. org/ 10. 3945/ ajcn. 115. 118935
 39. Egert S, Fobker M, Andersen G, Somoza V, Erbersdobler HF, 
Wahrburg U (2008) Effects of dietary alpha-linolenic acid, eicosa-
pentaenoic acid or docosahexaenoic acid on parameters of glucose 
metabolism in healthy volunteers. Ann Nutr Metab 53(3–4):182–
187. https:// doi. org/ 10. 1159/ 00017 2980
 40. Jovanovski E, Li D, Thanh Ho HV, Djedovic V, Ruiz Marques 
AC, Shishtar E, Mejia SB, Sievenpiper JL, de Souza RJ, Duvnjak 
L, Vuksan V (2017) The effect of alpha-linolenic acid on gly-
cemic control in individuals with type 2 diabetes: a systematic 
review and meta-analysis of randomized controlled clinical trials. 
Medicine 96(21):e6531. https:// doi. org/ 10. 1097/ md. 00000 00000 
006531
 41. Choque B, Catheline D, Rioux V, Legrand P (2014) Linoleic acid: 
between doubts and certainties. Biochimie 96:14–21. https:// doi. 
org/ 10. 1016/j. biochi. 2013. 07. 012
 42. Kapoor R, Huang YS (2006) Gamma linolenic acid: an antiinflam-
matory omega-6 fatty acid. Curr Pharm Biotechnol 7(6):531–534. 
https:// doi. org/ 10. 2174/ 13892 01067 79116 874
 43. Dow C, Mangin M, Balkau B, Affret A, Boutron-Ruault MC, 
Clavel-Chapelon F, Bonnet F, Fagherazzi G (2016) Fatty acid 
consumption and incident type 2 diabetes: an 18-year follow-up in 
the female E3N (Etude Epidémiologique auprès des femmes de la 
Mutuelle Générale de l’Education Nationale) prospective cohort 
study. Br J Nutr. https:// doi. org/ 10. 1017/ s0007 11451 60038 83
 44. Simopoulos AP (2008) The importance of the omega-6/omega-3 
fatty acid ratio in cardiovascular disease and other chronic dis-
eases. Exp Biol Med (Maywood) 233(6):674–688. https:// doi. org/ 
10. 3181/ 0711- mr- 311
 45. Whelan J (2008) The health implications of changing linoleic acid 
intakes. Prostaglandins Leukot Essent Fatty Acids 79(3–5):165–
167. https:// doi. org/ 10. 1016/j. plefa. 2008. 09. 013
 46. de Rooij SR, Nijpels G, Nilsson PM, Nolan JJ, Gabriel R, Bobbi-
oni-Harsch E, Mingrone G, Dekker JM (2009) Low-grade chronic 
inflammation in the relationship between insulin sensitivity and 
cardiovascular disease (RISC) population: associations with 
insulin resistance and cardiometabolic risk profile. Diabetes Care 
32(7):1295–1301. https:// doi. org/ 10. 2337/ dc08- 1795
European Journal of Nutrition 
1 3
 47. Weber N, Richter KD, Schulte E, Mukherjee KD (1995) Pet-
roselinic acid from dietary triacylglycerols reduces the con-
centration of arachidonic acid in tissue lipids of rats. J Nutr 
125(6):1563–1568. https:// doi. org/ 10. 1093/ jn/ 125.6. 1563
 48. Burdock GA, Carabin IG (2007) Safety assessment of myristic 
acid as a food ingredient. Food Chem Toxicol Int J Publ Br Ind 
Biol Res Assoc 45(4):517–529. https:// doi. org/ 10. 1016/j. fct. 2006. 
10. 009
 49. Lee Y, Lai HTM, de Oliveira Otto MC, Lemaitre RN, McKnight 
B, King IB, Song X, Huggins GS, Vest AR, Siscovick DS, Mozaf-
farian D (2020) Serial biomarkers of de novo lipogenesis fatty 
acids and incident heart failure in older adults: the cardiovascular 
health study. J Am Heart Assoc 9(4):e014119. https:// doi. org/ 10. 
1161/ jaha. 119. 014119
 50. Qureshi W, Santaren ID, Hanley AJ, Watkins SM, Lorenzo C, 
Wagenknecht LE (2019) Risk of diabetes associated with fatty 
acids in the de novo lipogenesis pathway is independent of insulin 
sensitivity and response: the Insulin Resistance Atherosclerosis 
Study (IRAS). BMJ Open Diabetes Res Care 7(1):e000691. 
https:// doi. org/ 10. 1136/ bmjdrc- 2019- 000691
 51. Lankinen MA, Stancakova A, Uusitupa M, Agren J, Pihlajamaki 
J, Kuusisto J, Schwab U, Laakso M (2015) Plasma fatty acids 
as predictors of glycaemia and type 2 diabetes. Diabetologia 
58(11):2533–2544. https:// doi. org/ 10. 1007/ s00125- 015- 3730-5
 52. Lindstrom J, Tuomilehto J (2003) The diabetes risk score: a 
practical tool to predict type 2 diabetes risk. Diabetes Care 
26(3):725–731
 53. Camargo A, Jimenez-Lucena R, Alcala-Diaz JF, Rangel-Zuniga 
OA, Garcia-Carpintero S, Lopez-Moreno J, Blanco-Rojo R, Del-
gado-Lista J, Perez-Martinez P, van Ommen B, Malagon MM, 
Ordovas JM, Perez-Jimenez F, Lopez-Miranda J (2019) Post-
prandial endotoxemia may influence the development of type 
2 diabetes mellitus: from the CORDIOPREV study. Clin Nutr 
(Edinburgh, Scotland) 38(2):529–538. https:// doi. org/ 10. 1016/j. 
clnu. 2018. 03. 016
Authors and Affiliations
Alejandro Villasanta‑Gonzalez1,2,3,4 · Juan Francisco Alcala‑Diaz1,2,3,4 · Cristina Vals‑Delgado1,2,3,4 · 
Antonio Pablo Arenas1,2,3,4 · Magdalena P. Cardelo1,2,3,4 · Juan Luis Romero‑Cabrera1,2,3,4 · 
Fernando Rodriguez‑Cantalejo5 · Javier Delgado‑Lista1,2,3,4 · Maria M. Malagon3,4,6 · Pablo Perez‑Martinez1,2,3,4 · 
Matthias B. Schulze7,8,9 · Antonio Camargo1,2,3,4 · Jose Lopez‑Miranda1,2,3,4
1 Lipids and Atherosclerosis Unit, Internal Medicine Unit, 
Reina Sofia University Hospital, Av. Menendez Pidal, s/n., 
14004 Córdoba, Spain
2 Department of Medicine, University of Cordoba, Córdoba, 
Spain
3 Instituto Maimonides de Investigación Biomedica de 
Cordoba (IMIBIC), Córdoba, Spain
4 CIBER Fisiopatología de la Obesidad y Nutrición 
(CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
5 Biochemical Laboratory, Reina Sofia University Hospital, 
Córdoba, Spain
6 Department of Cell Biology, Physiology and Immunology, 
University of Cordoba, Córdoba, Spain
7 German Center for Diabetes Research (DZD), 
München-Neuherberg, Germany
8 Department of Molecular Epidemiology, German Institute 
of Human Nutrition Potsdam-Rehbrücke, Nuthetal, Germany
9 Institute of Nutrition Science, University of Potsdam, 
Nuthetal, Germany
